|
End of period 1 predictor
|
Odds ratio (95% CI)
|
P value
|
|---|
|
SJC28 = 0 vs > 0
|
2.1 (1.4, 3.0)
|
< 0.001
|
|
TJC28 = 0 vs > 0
|
1.7 (1.2, 2.5)
|
0.003
|
|
Study
|
0.008
|
|
PRESERVE vs T2T
|
0.7 (0.4, 1.2)
| |
|
PRIZE vs T2T
|
1.7 (0.8, 3.5)
| |
|
Sustained deep remission vs not sustained remission
|
2.4 (1.5, 3.9)
|
< 0.001
|
|
ESR ≤ ULN vs > ULN
|
2.7 (1.5, 4.8)
|
0.001
|
|
Treatment
|
< 0.001
|
|
ETN 25 mg + MTX vs PBO + MTX
|
2.7 (1.7, 4.3)
| |
|
ETN 50 mg + MTX vs PBO + MTX
|
3.3 (2.1, 5.0)
| |
|
MTX vs PBO
|
0.7 (0.3, 1.7)
| |
- The subset of significant predictors was determined using a stepwise model with the following “end of period 1” predictors: sustained deep remission vs not; age in 10-year units; gender; body mass index ≤ 18.5, > 18.5 to ≤ 30, 30; HAQ ≤ 0.5 vs > 0.5; ESR ≤ ULN vs > ULN; SJC28 = 0 vs > 0; TJC28 = 0 vs > 0; study; treatment group
- CI confidence interval, ESR erythrocyte sedimentation rate, ETN etanercept, HAQ health assessment questionnaire, MTX methotrexate, PBO placebo, SJC28 swollen joint count measured using 28 joints, TJC28 tender joint count measured using 28 joints, ULN upper limit of normal
